Alzheon IPO take two: Will investors back a downsized offering from an Alzheimer’s biotech?
Alzheon couldn’t manage to pull off an $80 million IPO as a string of biotechs lined up to go public earlier this year. So now the biotech’s executive crew will take a shot at about half that much money as they look to engage some investors who would like to tread in the ultra-risky field of Alzheimer’s drug reclamation work.
The biotech, run by Martin Tolar, pulled back from the market just 4 months ago, unable to float shares. It filed anew on Monday, still focused on raising cash to get its drug ALZ-801 back into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
